April Armstrong

Keeping It Real: Real-World Brodalumab Outcomes in the Context of Pivotal Trials for Moderate-to-Severe Plaque Psoriasis

Introduction Brodalumab is the only interleukin-17 (IL-17) receptor A blocker approved for moderate-to-severe plaque psoriasis and blocks downstream signaling of multiple IL-17 isoforms including IL-17A, IL-17F, IL-17C, IL-17E, and IL-17A/F. Here, we contextualize effectiveness and safety of brodalumab in adult patient...